About Us / Overview

About Us

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for Neglected Diseases.

See DNDi's vision&mission and objectives.

To learn more about DNDi's activities and patients, download our short Presentation Brochure!

DNDi is working on the following diseases:

In 2011, DNDi started taking on specific projects for two new disease areas:

Paediatric HIV
Helminth infections (and more specifically filarial diseases)

Working in partnership with private industry, public institutions, academia and NGOs, DNDi has built the largest ever R&D portfolio for the kinetoplastid diseases and has currently underway five projects in Implementation stage, seven in the clinical, and seven in the pre-clinical.
To date, DNDi has successfully delivered

2 antimalarial treatments: ASAQ in 2007 and ASMQ in 2008 respectively
1 new treatment against Sleeping Sickness: NECT in 2009
1 new treatment against Visceral Leishmaniasis (VL): SSG&PM in 2010
a set of treatments for VL in Asia in 2011
a paediatric dosage form of benznidazole for Chagas disease in 2011

DNDi initiates and coordinates drug R&D projects in collaboration with

the international research community
the public sector
the pharmaceutical industry
and other relevant partners.

DNDi is also working to strengthen existing capacities in disease-endemic countries.

Learn more about DNDi's

and 7 DNDi regional offices in North America, Kenya, India, Brazil, Malaysia, Japan and DRC

See DNDi Worldwide

Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License